ChromoCure (Genome Research Group) Adds Full Spectrum ChromoSomal Scan Capability for Broad Base Cancer Progression Assessment:
17 Maggio 2010 - 2:30PM
Marketwired
ChromoCure, Inc. (Genome Research Group, Inc.) (PINKSHEETS: KKUR)
announced today the addition of its broad base ChromoSomal Scan as
part of its detection and progression assessment design, further
strengthening the Company's leadership in Cancer Detection, Therapy
and Cure, and puts new impetus to its groundbreaking Project
Boveri: Finding the Cure.
These new capabilities allow for comprehensive DNA-index
quantification and precise measurement of chromosomal imbalance
ratios and amounts; thereby providing increasing the value of vital
cancer progression analysis data for the precise assessment
remission rates and protocol efficacy in the Company's expanded
Therapeutic Research initiatives worldwide.
The Company's cancer detection technology is based on the
chromosomal theory of cancer. Research has conclusively and
irrefutably demonstrated aneuploidy a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today. The Company's cancer detection system locates and
measures unique genomic characteristics found in 100% of all
cancers and never found in normal cells. The Company's detection
technology has an effective 100% accuracy rate and an effective
100% specificity therefore making "false positives" and "false
negatives" theoretically impossible.
The Company possesses advanced detection and therapeutic
technology and protocols, comprised of ChromoCure's advanced
detection system and GRG's full line of therapeutic protocols and
technology; allowing for the first time real-time progression
monitoring and remission detection -- providing the world's first
cure research fully integrated system for the precise measurement
of treatment and on-demand, real-time cancer progression analysis
to monitor and determine treatment efficacy.
As a result of the recent merger and acquisition of Genome
Research Group, the combined entity possesses complementary
detection and therapeutic technology and protocols.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research. The Mayo Clinic's recent landmark findings confirming
aneuploidy as the cause of cancer were published in the December
2009 Cancer Cell journal. This publication has spurred increased
worldwide research by a number of respected research universities
and institutions, all of which have published similar reports in
2010.
This announcement, together with the recently announced Clinical
Testing and Trials for its landmark ChromoSomal Scanning Technology
as applied to cervical cancer and the Euro Zone launch of its
Pathologist Collaborative Research (PCR) Program in support of the
groundbreaking Project Boveri: Find the Cure Initiative, further
establishes the Company's leading role in the new era of cancer
research, detection, and therapy, as the companies leverage their
combined technologies, research knowledge and industry
relationships.
Management believes these initiatives to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation.
About Genome Research Group, Inc. (ChromoCure,
Inc.)
The Company develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has a proven
and effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research. The Company owns proprietary cancer
detection systems and related therapeutic technologies and
proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. GRG's advanced
Therapeutic Modeling and Treatment Protocols combined with its
industry and medical research collaborations validate its
leadership role in Cancer Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Set 2023 a Set 2024